Isothermal Nucleic Acid Amplification Technology Market Size By Technology, Product, Application, End-use, Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022

Description

List of Tables

The isothermal nucleic acid amplification technology (INAAT) market is expected to witness notable growth by 2028 on account of notable advancements in diagnostic technology. In addition, growing foreign investments in research and development activities, along with expanding demand for point-of-care (PoC) testing, are set to further boost industry progress through the forecast timespan.

The coronavirus pandemic has positively impacted the market landscape, INAAT offers easy detection and minimal operation qualities, which has promoted technology adoption. Moreover, prevalent focus on fabricating innovative INAAT tools for easy use in COVID-19 testing has enhanced overall market dynamics during the pandemic.

For instance, in March 2022, a study published in Global Challenges found that T-cup, a low-cost home device for isothermal nucleic acid amplification, could be used to detect the SARS-CoV2 RNA through loop-mediated amplification (LAMP) tests. The t-cup device is easier to produce and use as well as has little environmental impact compared to existing devices available in the market.

The isothermal nucleic acid amplification technology (INAAT) market has been split with respect to product, technology, application, end-use, and region. Based on technology, the industry has been further divided into helicase-dependent amplification (HDA), strand displacement amplification, loop-mediated isothermal amplification, nucleic acid sequence-based amplification (NASBA), and other technologies. The SDA technology segment is projected to witness significant growth at around 12% CAGR over the study period owing to rising demand to achieve the detection of pathogens in cancer.

In terms of product, the isothermal nucleic acid amplification technology (INAAT) market has been categorized into instruments and reagents. The instruments segment was valued at more than USD 383 million in 2021 and is foreseen to grow steadily over 2022-2028. Mounting demand for technologically advanced diagnostic equipment across different regions is expected to foster segmental expansion in the analysis period.

With regards to application, the INAAT market has been classified into oncology, infectious diseases, blood screening, and others. The oncology segment is estimated to depict approximately 12% CAGR through the review time period on account of the growing cancer patient pool across the globe.

With reference to end-use, the isothermal nucleic acid amplification technology (INAAT) market has been segregated into hospitals, diagnostic laboratories, and others. In 2021, the diagnostic laboratories segment was valued at above USD 380 million and is primed to observe strong growth through 2028. This growth is attributed to surging awareness about diagnostic facilities.

With respect to the region covered, the Latin America isothermal nucleic acid amplification technology (INAAT) market is anticipated to grow substantially at a CAGR of nearly 13% over the review period.

Product Code: 5251

Chapter 1 Methodology

1.1 Methodology
1.2 Market definitions
1.3 Forecast parameters
1.4 Data sources
- 1.4.1 Secondary
  - 1.4.1.1 Paid sources
  - 1.4.1.2 Unpaid sources
- 1.4.2 Primary

Chapter 2 Executive Summary

2.1 Isothermal Nucleic Acid Amplification Technology (INAAT) testing industry 360 degree synopsis, 2017 - 2028
- 2.1.1 Business trends
- 2.1.2 Technology trends
- 2.1.3 Products trends
- 2.1.4 Application trends
- 2.1.5 End-use trends
- 2.1.6 Regional trends

Chapter 3 Isothermal Nucleic Acid Amplification Technology (INAAT) Industry Insights

3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2028
3.3 Industry impact forces
- 3.3.1 Growth drivers
  - 3.3.1.1 Rising prevalence of infectious diseases
  - 3.3.1.2 Increasing adoption of INAAT over PCR
  - 3.3.1.3 Increasing blood transfusion
  - 3.3.1.4 Rise in demand for low-cost and effective diagnostics procedures
  - 3.3.1.5 Technological advancements to boost market growth
- 3.3.2 Industry pitfalls & challenges
  - 3.3.2.1 Lack of awareness about new diagnostics technologies
  - 3.3.2.2 Opposition from PCR technologies will pose a major challenge
3.4 Growth potential analysis
- 3.4.1 By technology
- 3.4.2 By product
- 3.4.3 By application
- 3.4.4 By end-use
3.5 COVID-19 impact analysis
3.6 Porter's analysis
3.7 Competitive landscape, 2021
- 3.7.1 Company matrix analysis, 2021
3.8 PESTEL analysis

Chapter 4 Isothermal Nucleic Acid Amplification Technology (INAAT) Market, By Technology

4.1 Key segment trends
4.2 Loop-mediated Isothermal Amplification (LAMP)
- 4.2.1 Market size, by region, 2017 - 2028 (USD Million)
4.3 Strand Displacement Amplification (SDA)
- 4.3.1 Market size, by region, 2017 - 2028 (USD Million)
4.4 Nucleic Acid Sequence-based Amplification (NASBA)
- 4.4.1 Market size, by region, 2017 - 2028 (USD Million)
4.5 Helicase-dependent Amplification (HDA)
- 4.5.1 Market size, by region, 2017 - 2028 (USD Million)
4.6 Others
- 4.6.1 Market size, by region, 2017 - 2028 (USD Million)

Chapter 5 Isothermal Nucleic Acid Amplification Technology (INAAT) Market, By Product

5.1 Key segment trends
5.2 Instruments
- 5.2.1 Market size, by region, 2017 - 2028 (USD Million)
5.3 Reagents
- 5.3.1 Market size, by region, 2017 - 2028 (USD Million)

Chapter 6 Isothermal Nucleic Acid Amplification Technology (INAAT) Market, By Application

6.1 Key segment trends
6.2 Infectious disease
- 6.2.1 Market size, by region, 2017 - 2028 (USD Million)
- 6.2.2 HIV
  - 6.2.2.1 Market size, by region, 2017 - 2028 (USD Million)
- 6.2.3 Influenza
  - 6.2.3.1 Market size, by region, 2017 - 2028 (USD Million)
- 6.2.4 Malaria
  - 6.2.4.1 Market size, by region, 2017 - 2028 (USD Million)
- 6.2.5 Tuberculosis
  - 6.2.5.1 Market size, by region, 2017 - 2028 (USD Million)
6.3 Oncology
- 6.3.1 Market size, by region, 2017 - 2028 (USD Million)
6.4 Blood Screening
- 6.4.1 Market size, by region, 2017 - 2028 (USD Million)
6.5 Others
- 6.5.1 Market size, by region, 2017 - 2028 (USD Million)

Chapter 7 Isothermal Nucleic Acid Amplification Technology (INAAT) Market, By End-use

7.1 Key segment trends
7.2 Hospitals
- 7.2.1 Market size, by region, 2017 - 2028 (USD Million)
7.3 Diagnostic Laboratories
- 7.3.1 Market size, by region, 2017 - 2028 (USD Million)
7.4 Others
- 7.4.1 Market size, by region, 2017 - 2028 (USD Million)

Chapter 8 Isothermal Nucleic Acid Amplification Technology (INAAT) Market, By Region

8.1 Key regional trends
8.2 North America
- 8.2.1 Market size, by country, 2017 - 2028 (USD Million)
- 8.2.2 Market size, by technology, 2017 - 2028 (USD Million)
- 8.2.3 Market size, by product, 2017 - 2028 (USD Million)
- 8.2.4 Market size, by application, 2017 - 2028 (USD Million)
  - 8.2.4.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
- 8.2.5 Market size, by end-use, 2017 - 2028 (USD Million)
- 8.2.6 U.S.
  - 8.2.6.1 Market size, by technology, 2017 - 2028 (USD Million)
  - 8.2.6.2 Market size, by product, 2017 - 2028 (USD Million)
  - 8.2.6.3 Market size, by application, 2017 - 2028 (USD Million)
    - 8.2.6.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
  - 8.2.6.4 Market size, by end-use, 2017 - 2028 (USD Million)
- 8.2.7 Canada
  - 8.2.7.1 Market size, by technology, 2017 - 2028 (USD Million)
  - 8.2.7.2 Market size, by product, 2017 - 2028 (USD Million)
  - 8.2.7.3 Market size, by application, 2017 - 2028 (USD Million)
    - 8.2.7.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
  - 8.2.7.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.3 Europe
- 8.3.1 Market size, by country, 2017 - 2028 (USD Million)
- 8.3.2 Market size, by technology, 2017 - 2028 (USD Million)
- 8.3.3 Market size, by product, 2017 - 2028 (USD Million)
- 8.3.4 Market size, by application, 2017 - 2028 (USD Million)
  - 8.3.4.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
- 8.3.5 Market size, by end-use, 2017 - 2028 (USD Million)
- 8.3.6 Germany
  - 8.3.6.1 Market size, by technology, 2017 - 2028 (USD Million)
  - 8.3.6.2 Market size, by product, 2017 - 2028 (USD Million)
  - 8.3.6.3 Market size, by application, 2017 - 2028 (USD Million)
    - 8.3.6.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
  - 8.3.6.4 Market size, by end-use, 2017 - 2028 (USD Million)
- 8.3.7 UK
  - 8.3.7.1 Market size, by technology, 2017 - 2028 (USD Million)
  - 8.3.7.2 Market size, by product, 2017 - 2028 (USD Million)
  - 8.3.7.3 Market size, by application, 2017 - 2028 (USD Million)
    - 8.3.7.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
  - 8.3.7.4 Market size, by end-use, 2017 - 2028 (USD Million)
- 8.3.8 France
  - 8.3.8.1 Market size, by technology, 2017 - 2028 (USD Million)
  - 8.3.8.2 Market size, by product, 2017 - 2028 (USD Million)
  - 8.3.8.3 Market size, by application, 2017 - 2028 (USD Million)
    - 8.3.8.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
  - 8.3.8.4 Market size, by end-use, 2017 - 2028 (USD Million)
- 8.3.9 Italy
  - 8.3.9.1 Market size, by technology, 2017 - 2028 (USD Million)
  - 8.3.9.2 Market size, by product, 2017 - 2028 (USD Million)
  - 8.3.9.3 Market size, by application, 2017 - 2028 (USD Million)
    - 8.3.9.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
  - 8.3.9.4 Market size, by end-use, 2017 - 2028 (USD Million)
- 8.3.10 Spain
  - 8.3.10.1 Market size, by technology, 2017 - 2028 (USD Million)
  - 8.3.10.2 Market size, by product, 2017 - 2028 (USD Million)
  - 8.3.10.3 Market size, by application, 2017 - 2028 (USD Million)
    - 8.3.10.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
  - 8.3.10.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.4 Asia Pacific
- 8.4.1 Market size, by country, 2017 - 2028 (USD Million)
- 8.4.2 Market size, by technology, 2017 - 2028 (USD Million)
- 8.4.3 Market size, by product, 2017 - 2028 (USD Million)
- 8.4.4 Market size, by application, 2017 - 2028 (USD Million)
  - 8.4.4.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
- 8.4.5 Market size, by end-use, 2017 - 2028 (USD Million)
- 8.4.6 China
  - 8.4.6.1 Market size, by technology, 2017 - 2028 (USD Million)
  - 8.4.6.2 Market size, by product, 2017 - 2028 (USD Million)
  - 8.4.6.3 Market size, by application, 2017 - 2028 (USD Million)
    - 8.4.6.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
  - 8.4.6.4 Market size, by end-use, 2017 - 2028 (USD Million)
- 8.4.7 Japan
  - 8.4.7.1 Market size, by technology, 2017 - 2028 (USD Million)
  - 8.4.7.2 Market size, by product, 2017 - 2028 (USD Million)
  - 8.4.7.3 Market size, by application, 2017 - 2028 (USD Million)
    - 8.4.7.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
  - 8.4.7.4 Market size, by end-use, 2017 - 2028 (USD Million)
- 8.4.8 India
  - 8.4.8.1 Market size, by technology, 2017 - 2028 (USD Million)
  - 8.4.8.2 Market size, by product, 2017 - 2028 (USD Million)
  - 8.4.8.3 Market size, by application, 2017 - 2028 (USD Million)
    - 8.4.8.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
  - 8.4.8.4 Market size, by end-use, 2017 - 2028 (USD Million)
- 8.4.9 Australia
  - 8.4.9.1 Market size, by technology, 2017 - 2028 (USD Million)
  - 8.4.9.2 Market size, by product, 2017 - 2028 (USD Million)
  - 8.4.9.3 Market size, by application, 2017 - 2028 (USD Million)
    - 8.4.9.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
  - 8.4.9.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.5 Latin America
- 8.5.1 Market size, by country, 2017 - 2028 (USD Million)
- 8.5.2 Market size, by technology, 2017 - 2028 (USD Million)
- 8.5.3 Market size, by product, 2017 - 2028 (USD Million)
- 8.5.4 Market size, by application, 2017 - 2028 (USD Million)
  - 8.5.4.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
- 8.5.5 Market size, by end-use, 2017 - 2028 (USD Million)
- 8.5.6 Brazil
  - 8.5.6.1 Market size, by technology, 2017 - 2028 (USD Million)
  - 8.5.6.2 Market size, by product, 2017 - 2028 (USD Million)
  - 8.5.6.3 Market size, by application, 2017 - 2028 (USD Million)
    - 8.5.6.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
  - 8.5.6.4 Market size, by end-use, 2017 - 2028 (USD Million)
- 8.5.7 Mexico
  - 8.5.7.1 Market size, by technology, 2017 - 2028 (USD Million)
  - 8.5.7.2 Market size, by product, 2017 - 2028 (USD Million)
  - 8.5.7.3 Market size, by application, 2017 - 2028 (USD Million)
    - 8.5.7.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
  - 8.5.7.4 Market size, by end-use, 2017 - 2028 (USD Million)
8.6 Middle East & Africa
- 8.6.1 Market size, by country, 2017 - 2028 (USD Million)
- 8.6.2 Market size, by technology, 2017 - 2028 (USD Million)
- 8.6.3 Market size, by product, 2017 - 2028 (USD Million)
- 8.6.4 Market size, by application, 2017 - 2028 (USD Million)
  - 8.6.4.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
- 8.6.5 Market size, by end-use, 2017 - 2028 (USD Million)
- 8.6.6 Saudi Arabia
  - 8.6.6.1 Market size, by technology, 2017 - 2028 (USD Million)
  - 8.6.6.2 Market size, by product, 2017 - 2028 (USD Million)
  - 8.6.6.3 Market size, by application, 2017 - 2028 (USD Million)
    - 8.6.6.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
  - 8.6.6.4 Market size, by end-use, 2017 - 2028 (USD Million)
- 8.6.7 South Africa
  - 8.6.7.1 Market size, by technology, 2017 - 2028 (USD Million)
  - 8.6.7.2 Market size, by product, 2017 - 2028 (USD Million)
  - 8.6.7.3 Market size, by application, 2017 - 2028 (USD Million)
    - 8.6.7.3.1 Market size, by infectious disease, 2017 - 2028 (USD Million)
  - 8.6.7.4 Market size, by end-use, 2017 - 2028 (USD Million)

Chapter 9 Company Profiles

9.1 Competitive dashboard, 2021
9.2 Becton, Dickinson and Company
- 9.2.1 Business overview
- 9.2.2 Financial data
- 9.2.3 Product landscape
- 9.2.4 Strategic outlook
- 9.2.5 SWOT analysis
9.3 Abbott (Alere)
- 9.3.1 Business overview
- 9.3.2 Financial data
- 9.3.3 Product landscape
- 9.3.4 Strategic outlook
- 9.3.5 SWOT analysis
9.4 BioMerieux SA
- 9.4.1 Business overview
- 9.4.2 Financial data
- 9.4.3 Product landscape
- 9.4.4 Strategic outlook
- 9.4.5 SWOT analysis
9.5 Eiken Chemical Co. Ltd
- 9.5.1 Business overview
- 9.5.2 Financial data
- 9.5.3 Product landscape
- 9.5.4 Strategic outlook
- 9.5.5 SWOT analysis
9.6 Hologic Inc. (Gen-Probe)
- 9.6.1 Business overview
- 9.6.2 Financial data
- 9.6.3 Product landscape
- 9.6.4 Strategic outlook
- 9.6.5 SWOT analysis
9.7 Lucigen
- 9.7.1 Business overview
- 9.7.2 Financial data
- 9.7.3 Product landscape
- 9.7.4 Strategic outlook
- 9.7.5 SWOT analysis
9.8 Meridian Bioscience, Inc.
- 9.8.1 Business overview
- 9.8.2 Financial data
- 9.8.3 Product landscape
- 9.8.4 Strategic outlook
- 9.8.5 SWOT analysis
9.9 OptiGene Limited
- 9.9.1 Business overview
- 9.9.2 Financial data
- 9.9.3 Product landscape
- 9.9.4 Strategic outlook
- 9.9.5 SWOT analysis
9.10 Qiagen NV
- 9.10.1 Business overview
- 9.10.2 Financial data
- 9.10.3 Product landscape
- 9.10.4 Strategic outlook
- 9.10.5 SWOT analysis
9.11 Quidel Corporation
- 9.11.1 Business overview
- 9.11.2 Financial data
- 9.11.3 Product landscape
- 9.11.4 Strategic outlook
- 9.11.5 SWOT analysis
9.12 Tecan Genomics Inc.
- 9.12.1 Business overview
- 9.12.2 Financial data
- 9.12.3 Product landscape
- 9.12.4 Strategic outlook
- 9.12.5 SWOT analysis
9.13 Thermo Fisher Scientific Inc.
- 9.13.1 Business overview
- 9.13.2 Financial data
- 9.13.3 Product landscape
- 9.13.4 Strategic outlook
- 9.13.5 SWOT analysis
9.14 Ustar Biotechnologies Ltd.
- 9.14.1 Business overview
- 9.14.2 Financial data
- 9.14.3 Product landscape
- 9.14.4 Strategic outlook
- 9.14.5 SWOT analysis
9.15 Grifols, S.A.
- 9.15.1 Business overview
- 9.15.2 Financial data
- 9.15.3 Product landscape
- 9.15.4 Strategic outlook
- 9.15.5 SWOT analysis